Medical Policy

Effective Date:12/01/2011 Title:Magnetoenchalopgraphy (MEG)
Revision Date:10/01/2015 Document:BI329:00
CPT Code(s):95965-95967, S8035
Public Statement

Effective Date:

a)    This policy will apply to all services performed on or after the above revision date which will become the new effective date.

b)    For all services referred to in this policy that were performed before the revision date, contact customer service for the rules that would apply.

  1. Magnetoencephalography is a noninvasive functional imaging technique which records the weak magnetic forces associated with the brain’s electrical activity. 
  2. This sophisticated technique is sometimes helpful in localizing brain function in patients preparing to undergo brain surgery for intractable epilepsy.
  3. This technology is covered in patients who meet the medical policy criteria for intractable epilepsy.
Medical Statement
  1. Magnetic source imaging (MSI) or magnetoencephalography (MEG) are considered medically necessary for pre-surgical evaluation in persons with intractable focal epilepsy to identify and localize areas of epileptiform activity, when discordance or continuing questions arise from among other techniques designed to localize a focus.
  2. MSI or MEG is considered experimental and investigational when used as a stand-alone test or as the first order of test after clinical and routine electroencephalographic (EEG) diagnosis of epilepsy.

 

Codes Used In This BI:

95965 Magnetoencephalography (MEG), recording and analysis; for spontaneous brain magnetic activity (e.g., epileptic cerebral cortex localization)
95966 Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, single modality (e.g., sensory, motor, language, or visual cortex localization)
95967 Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, each additional modality (e.g., sensory, motor, language, or visual cortex localization) (List separately in addition to code for primary procedure)
S8035 Magnetic source imaging
 

Limits

1.    MSI or MEG is considered experimental and investigational for the following indications (not an all inclusive list):

·         Evaluation of Alzheimer`s disease

·         Evaluation of autism

·         Evaluation of brain tumors

·         Evaluation of cognitive and mental disorders

·         Evaluation of developmental dyslexia

·         Evaluation of multiple sclerosis

·         Evaluation of Parkinson`s disease

·         Evaluation of schizophrenia

·         Evaluation of stroke rehabilitation

·         Evaluation of traumatic brain injury

·         Fetal neurological assessment.

Reference
  1. Blumenfeld LD, Clementz BA. Response to the first stimulus determines reduced auditory evoked response suppression in schizophrenia: Single trials analysis using MEG. Clin Neurophysiol. 2001; 112(9):1650-1659.
  2. Zappasodi F, Tecchio F, Pizzella V, et al. Detection of fetal auditory evoked responses by means of magnetoencephalography. Brain Res. 2001; 917(2):167-173.
  3. Rosenow F, Luders H. Presurgical evaluation of epilepsy. Brain. 2001; 124(Pt 9):1683-1700.
  4. Filipek PA, Accardo PJ, Ashwal S, et al. American Academy of Neurology. Practice parameter: Screening and diagnosis of autism. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology. 2000; 55(4):468-479.
  5. Kuzniecky RI, Knowlton RC. Neuroimaging of epilepsy. Semin Neurol. 2002; 22(3):279-288.
  6. Feichtinger M, Holl A, Korner E, Schrottner O, et al. Future aspects of the presurgical evaluation in epilepsy. Acta Neurochir Suppl. 2002; 84:17-26.
  7. Barkley GL. Controversies in neurophysiology. MEG is superior to EEG in localization of interictal epileptiform activity: Pro. Clin Neurophysiol. 2004; 115(5):1001-1009.
  8. Baumgartner C. Controversies in clinical neurophysiology. MEG is superior to EEG in the localization of interictal epileptiform activity: Con. Clin Neurophysiol. 2004; 115(5):1010-1020.
  9. Knowlton RC, Shih J. Magnetoencephalography in epilepsy. Epilepsia. 2004;45 Suppl 4:61-71.
  10. Parra J, Kalitzin SN, da Silva FH. Magnetoencephalography: An investigational tool or a routine clinical technique? Epilepsy Behav. 2004;5(3):277-285.
  11. Billingsley-Marshall RL, Simos PG, Papanicolaou AC. Reliability and validity of functional neuroimaging techniques for identifying language-critical areas in children and adults. Dev Neuropsychol. 2004;26(2):541-563.
  12. Stefan H, Hummel C, Scheler G, et al. Magnetic brain source imaging of focal epileptic activity: A synopsis of 455 cases. Brain. 2003;126(Pt 11):2396-2405.
  13. Lopes da Silva FH. What is magnetoencephalography and why it is relevant to neurosurgery? Adv Tech Stand Neurosurg. 2005;30:51-67.
  14. Pataraia E, Lindinger G, Deecke L, et al. Combined MEG/EEG analysis of the interictal spike complex in mesial temporal lobe epilepsy. Neuroimage. 2005;24(3):607-614.
  15. Papanicolaou AC, Pataraia E, Billingsley-Marshall R, et al. Toward the substitution of invasive electroencephalography in epilepsy surgery. J Clin Neurophysiol. 2005;22(4):231-237.
  16. Wirrell E, Whiting S, Farrell K. Management of intractable epilepsy in infancy and childhood. Adv Neurol. 2006;97:463-491.
  17. Knowlton RC, Elgavish R, Howell J, et al. Magnetic source imaging versus intracranial electroencephalogram in epilepsy surgery: A prospective study. Ann Neurol. 2006;59(5):835-842.
  18. Criado JR, Amo C, Quint P, et al. Using magnetoencephalography to study patterns of brain magnetic activity in Alzheimer`s disease. Am J Alzheimers Dis Other Demen. 2006;21(6):416-423.
  19. Ontario Ministry of Health, Medical Advisory Secretariat (MAS). Functional brain imaging. Health Technology Policy Assessment. Toronto, ON: MAS; December 2006. Available at: http://www.health.gov.on.ca/english/providers/program/mas/tech/reviews/pdf/
    rev_fbi_012507.pdf. Accessed April 3, 2007.
  20. Rampp S, Stefan H. Magnetoencephalography in presurgical epilepsy diagnosis. Expert Rev Med Devices. 2007;4(3):335-347.
  21. Poza J, Hornero R, Abásolo D, et al. Evaluation of spectral ratio measures from spontaneous MEG recordings in patients with Alzheimer`s disease. Comput Methods Programs Biomed. 2008;90(2):137-147.
  22. Lau M, Yam D, Burneo JG. A systematic review on MEG and its use in the presurgical evaluation of localization-related epilepsy. Epilepsy Res. 2008;79(2-3):97-104.
  23. Leijten FS, Huiskamp G. Interictal electromagnetic source imaging in focal epilepsy: Practices, results and recommendations. Curr Opin Neurol. 2008;21(4):437-445.
  24. Korvenoja A, Kirveskari E, Aronen HJ, et al. Sensorimotor cortex localization: Comparison of magnetoencephalography, functional MR imaging, and intraoperative cortical mapping. Radiology. 2006;241(1):213-222.
  25. Grover KM, Bowyer SM, Rock J, et al. Retrospective review of MEG visual evoked hemifield responses prior to resection of temporo-parieto-occipital lesions. J Neurooncol. 2006;77(2):161-166.
  26. Pelletier I, Sauerwein HC, Lepore F, et al. Non-invasive alternatives to the Wada test in the presurgical evaluation of language and memory functions in epilepsy patients. Epileptic Disord. 2007;9(2):111-126.
  27. Sutherling WW, Mamelak AN, Thyerlei D, et al. Influence of magnetic source imaging for planning intracranial EEG in epilepsy. Neurology. 2008;71(13):990-996.
  28. Knowlton RC, Elgavish RA, Limdi N, et al. Functional imaging: I. Relative predictive value of intracranial electroencephalography. Ann Neurol. 2008;64(1):25-34.
  29. Knowlton RC, Elgavish RA, Bartolucci A, et al. Functional imaging: II. Prediction of epilepsy surgery outcome. Ann Neurol. 2008;64(1):35-41.
  30. Knowlton RC. Can magnetoencephalography aid epilepsy surgery? Epilepsy Curr. 2008;8(1):1-5.
  31. American Academy of Neurology Professional Association (AANPA). Magnetoencephalography (MEG) Policy. Recommended by the AANPA Medical Economics and Management Committee. Approved by the AANPA Board of Directors on May 8, 2009. St. Paul, MN: AANPA; 2009.
  32. Bagic A, Funke ME, Ebersole J; ACMEGS Position Statement Committee. American Clinical MEG Society (ACMEGS) position statement: The value of magnetoencephalography (MEG)/magnetic source imaging (MSI) in noninvasive presurgical evaluation of patients with medically intractable localization-related epilepsy. J Clin Neurophysiol. 2009;26(4):290-293.
  33. Cimon K, Spry C. Magnetoencephalography (MEG) for seizure disorders in children: Clinical effectiveness. Health Technology Inquiry Service (HTIS). Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); September 2, 2009.
  34. Clark M, Spry C. Magnetoencephalography for neurocognitive disorders: Clinical effectiveness. Health Technology Inquiry Service (HTIS). Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); September 2, 2009.
  35. Funke M, Constantino T, Van Orman C, Rodin E. Magnetoencephalography and magnetic source imaging in epilepsy. Clin EEG Neurosci. 2009;40(4):271-280.
  36. Lowery CL, Govindan RB, Preissl H, et al. Fetal neurological assessment using noninvasive magnetoencephalography. Clin Perinatol. 2009;36(3):701-709.
  37. Stam CJ. Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders. J Neurol Sci. 2010;289(1-2):128-134.
  38. Siekmeier PJ, Stufflebeam SM. Patterns of spontaneous magnetoencephalographic activity in patients with schizophrenia. J Clin Neurophysiol. 2010;27(3):179-190.
  39. Haddad N, Govindan RB, Vairavan S, et al. Correlation between fetal brain activity patterns and behavioral states: An exploratory fetal magnetoencephalography study. Exp Neurol. 2011 Jan 13. [Epub ahead of print]
Application to Products
This policy applies to all health plans administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet. Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) for those plans insured by QualChoice. In the event of a discrepancy between this policy and a self-insured customer’s SPD or the specific QualChoice EOC, the SPD or EOC, as applicable, will prevail. State and federal mandates will be followed as they apply.

Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed.